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Objective: To establish feasibility of initiating electrical stimulation treatment of wrist 
extensors and flexors in patients early after stroke to prevent painful muscle contractures. 
 
Design: Feasibility randomised controlled trial with economic evaluation. 
 
Setting:  A specialist stroke unit in Nottinghamshire.   
 
Subjects: Forty patients with stroke and arm hemiparesis, recruited within 72 hours after 
stroke.   
 
Interventions: Participants were randomised to receive usual care or usual care and 
electrical stimulation to wrist flexors and extensors for 30 minutes, twice a day, five days a 
week for three months. Initial treatment was delivered by an occupational therapist or 
physiotherapist who trained the patient to self-manage subsequent treatments. 
 
Main measures: Measures of feasibility included recruitment and attrition rates, completion 
of treatment and successful data collection.  Outcome data on wrist range of motion, pain, 
arm function, independence, quality of life and resource use were measured at 3, 6 and 12 




Results: Forty participants recruited in 15 months [20 men; mean age 72 (SD 13.0)].  
Attrition at three month follow-up was 12.5% [death (n=2), end-of-life care (n=2), unable to 
contact (n=1)].  Compliance varied [mean 65 (SD 53)] and ranged from 10 to 166 ES 
treatment sessions per patient.  Target dosage was 120 sessions but participants were 
able to cease treatment when full arm function returned. Initial economic analysis 
suggested treatment was cost beneficial. 
 
Conclusion: Early initiation of ES treatment was acceptable and feasible when compared 
with usual care. The data collection methods used were shown to be feasible and 




Impaired arm function is a permanent and disabling problem for an estimated 40% of stroke 
survivors1,2. In the presence of persistent paresis, arm muscles atrophy rapidly and patients, 
particularly those with spasticity and pain, are at an increased risk of developing painful muscle 
contractures (fixed joint deformities)3.  Prevalence of hand and wrist contractures is unknown, but 
contractures can become established as early as six weeks after stroke3 and as many as 60% of 
care home dwelling stroke survivors develop at least one contracture within a year after a 
stroke4. It is possible that one cause for contracture is the lack of adequate upper limb therapy 
input1,5-6, i.e. on average patients spend between 0.9 and 7.9 minutes per physiotherapy session 
on arm rehabilitation7. 
 
Evidence suggests that early initiation (24 hours post-stroke) of rehabilitation interventions and 
high intensity of treatment can enhance the chances of neurological recovery8-12, however, there 
is also the potential for risk of harm13,14.  For those patients unlikely to make functional gains, 
prevention of complications such as pain and contractures (fixed joint deformity) should be the 
focus of therapeutic interventions and there is some evidence that treatment with electrical 
stimulation is of potential value15-18. Previous pilot trials of electrical stimulation have only 
focussed on stimulation of the extensor muscles and have not stimulated the flexor muscle group 
but have demonstrated some benefit in terms of slowing the rate of deterioration, and in some 
cases, facilitating recovery however effect sizes were small16-18.  These studies concluded that 
the treatment was not given for long enough and premature discontinuation of therapy may have 
reduced any potential therapeutic effect.  No extended trials have been conducted. Furthermore, 
the muscle at risk of shortening are the wrist and forearm flexors and the most effective method 
of loading the soft tissue structures of the flexors, in patients who are unable to fully activate their 
muscles, is by electrically stimulating these muscles. 
 
The aim of this study was to evaluate the feasibility of conducting a future definitive randomised 
controlled trial of the efficacy and cost effectiveness of early, intensive electrical stimulation to 
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prevent wrist joint deformities/muscle contractures, weakness and upper limb pain after stroke by 
stimulating the wrist flexors and extensors reciprocally. 
 
Methodology 
This single centre, unblinded randomised controlled trial was approved by the National Research 
Ethics Service, East Midlands Nottingham (UK) Research Ethics Committee (ref: 15/EM/0006) 
and was registered with ClinicalTrials.gov (Identifier: NCT02324634).  This research was funded 
by the National Institute for Health Research (Research for Patient Benefit Programme; ref PB-
PG-1013-32034).  The study was hosted by Nottingham University Hospitals National Health 
Service (NHS) Trust and coordinated by the University of Nottingham (the research sponsor). 
The full study protocol has been previously published in the British Medical Journal19 and is 
briefly described below. 
 
Patients admitted to Nottingham University Hospitals’ stroke unit were eligible for participation if 
recruitment could be conducted within 72 hours of stroke. All participants were required to 
provide written informed consent and an ‘aphasia friendly’ version of the information sheets and 
consent form were available for those with communication difficulties.  In cases where it was not 
possible to obtain informed consent from the patient due to communication and/or cognitive 
difficulties, consultee consent was obtained from the patient’s relative. 
 
Inclusion criteria 
 Confirmed clinical diagnosis of stroke  
 First stroke event to affect the upper limb 
 Aged >18 years 
 Impaired arm movement and strength caused by stroke (determined by the National 
Institute for Health Stroke Scale20 (NIHSS) arm sub score ≥1)  
 
Exclusion criteria 
 An existing chronic arm condition (e.g. peripheral nerve injury)  
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 Cardiac pacemaker (Patients with pacemakers were not included as access to a 
Cardiologist to confirm the safety of treatment for individual patients was not possible) 
 Pregnancy 
 Epilepsy 
 Undiagnosed pain or skin conditions affecting the arm (not related to the stroke)     
 
Consenting participants were independently randomised into an intervention or a control group 
using a telephone randomisation service. Minimisation was based on: age; sex; side of stroke; 
and severity of arm weakness (as measured by the NIHSS20 arm sub score). 
 
Usual care control  
Participants randomised to the control group did not receive electrical stimulation therapy but 
received all usual care (which did not include the use of surface neuromuscular electrical 
stimulation).  It was not possible to collect data on the nature or volume of usual care. 
 
Intervention treatment 
Participants randomised to the treatment group received treatment with electrical stimulation in 
addition to their routine care. Treatment with electrical stimulation was delivered using a two-
channel constant current stimulator (maximum output 100 mA, pulse width 450μs and a 
frequency between 40 to 60Hz as per participant preference)*A.  The current intensity was 
increased to produce an alternating contraction of the flexors and extensors using a flex-hold-
extend-hold pattern, ensuring that a pure movement was produced with no/minimal ulnar or 
radial deviation. A single stimulation and hold cycle lasted 20 seconds and this was cyclically 
repeated for 30 minutes (40 cycles of movement in a full treatment session). Treatment 
continued twice a day, 5 days a week (Monday to Friday), for a total period of 3 months. 
The total possible number of electrical stimulation treatments (as per protocol) was 120 treatment 




The motor points for stimulation were selected to produce reciprocal flexion and extension 
through full range of movement21.  The first treatment was provided by a qualified (NHS band 5 
or above) physiotherapist or occupational therapist who was trained to identify the motor points 
for electrical stimulation. Following the initial treatment, the skin was marked with a skin-safe 
marker pen to show the correct area to place the electrodes for future treatments and the 
electrical stimulation device was locked to the selected settings.  After the initial session, clinical 
staff (e.g. rehabilitation support workers, nursing support staff, or health care assistants) assisted 
the patient to apply the electrode pads to the pre-marked motor points and switch on the device 
with the pre-stored treatment setting (this took between 2-5 minutes) for subsequent treatments. 
Prior to hospital discharge, the patient and/or nominated carer were taught by a therapist how to 
self-manage the treatment.  
 
Outcome measures 
The primary outcomes related to feasibility aims: 
 Recruitment/participation and exclusion rates  
 Completion/attrition rates  
 Compliance/adherence to treatment protocol  
 Consultee consent rates  
 Outcome measure completion rates 
 
The secondary outcomes were demographic characteristics (age, gender, ethnicity and 
socioeconomic status), stroke characteristics (date, type and side of stroke), cognitive status 
(Montreal Cognitive Assessment - MoCA22) and Pre-morbid function state (Nottingham Extended 
ADL - NEADL23) were collected at baseline. In addition, participants completed the following 
assessments at 3, 6 and 12 months: 
 Neurological outcome (NIHSS20 score) 
 Independence in daily activities (Barthel ADL Index score24 and modified Rankin Scale – 
mRS25,26) 
 Pain in the affected arm (Scale of Pain Intensity - SPIN27) 
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 Spasticity (was measured as stretch induced activation of muscles as described in 
Malhotra et al3) 
 Arm function (Action Research Arm Test - ARAT28) 
 Stroke related quality of life (Stroke Specific Quality of Life scale -SS-QOL29) 
 Health status (EuroQol-5D - EQ-5D30) 
 Patient resource use questionnaire 
 Carer strain (Caregiver Strain Index - CSI31) completed by the participant’s nominated 
carer. 
Baseline assessments were completed on the stroke unit by the patient’s bedside and 3, 6, and 
12 month follow-ups were completed in the community at the patient’s discharge destination (e.g. 
home or care home). 
 
Statistical analysis & reporting 
 Total number of patients recruited within 72 hours of stroke event; average length of time 
post-stroke when patients received first treatment. 
 Total number or patients screened, eligible and approached, consented, and excluded 
after screening. 
 Total number of patients who completed the intervention; number who completed 3, 6 
and 12 month follow-up assessments. 
 Total number of participants receiving electrical stimulation per protocol (target number of 
treatments was 120); mean, minimum, and maximum number of electrical stimulation 
treatments received during the 3 month intervention period; qualitative patient/carer 
interview data, and electrical stimulation machine’s memory which records number of 
sessions and duration. 
 Total number of patients unable to give informed consent; Number consented by 
consultee; Number of consultees who declined. 
 Recruitment and attrition rates, number of patients lost to follow-up and reasons. 
 Median scores and IQR for outcome measures were calculated. 
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 Completion and quality of health economic data between assessment points especially 6 
to 12 months regarding sensitivity of the EQ5D-5L in measuring outcome.  Combined 
cost and outcome analysis to determine potential cost effectiveness of electrical 
stimulation verses usual care.  Exploration of feasibility of using some of the other 
outcome measurements to determine cost effectiveness. A purposively designed patient 
collection data resource proforma was constructed. 
 
Results 
Recruitment began on the 1st June 2015.  Of 215 potentially eligible patients, 40 were recruited 
in 15 months [20 men; mean age 72 years (SD 13.0)] (figure 1) 22 potentially eligible patients 
declined to participate.  Half of the participants (n=20) lacked the mental capacity to be able to 
provide informed consent and were therefore recruited by consultee consent. All participants 
were recruited within 72 hours following a first stroke and baseline characteristics are 
summarised in table 1, the treatment groups were well matched in terms of NIHSS arm score but 
participants in the control group had higher stroke severity (median NIHSS 15) compared to the 
electrical stimulation group (median NIHSS 9).  Attrition at 3-month follow-up was 12.5% [5/40] 
and at 12-months follow up was 32.5% [13/40].  Reasons for attrition are summarised in the 
CONSORT flow diagram (figure 1). 
 
The number of treatments received ranged from 10 to 166 with a mean of 64.5 (SD 53).  Five 
participants used the device in excess of the standard protocol (120 treatment sessions).  
Reasons for participants not receiving the target number of treatments included the electrical 
stimulation device being locked in the hospital bedside cabinet by stroke unit staff or placed out 
of reach of the patient, illness that prevented engagement in any rehabilitation for a period of 
time, or the participant regaining full functional use of the upper limb and therefore discontinuing 
treatment.  There was also one incident of protocol violation early on in the study, whereby a 
therapist did not agree with the concept of stimulating the flexor muscles and instead fabricated a 




The 3, 6 and 12 month outcome measure completion rates of the participants by treatment 
allocation are summarised in table 2. 
 
Of the 26 patients, 14 had an NIHSS arm score of zero (i.e. a marker of return in arm function), 
four had a score between one and three (a marker for some arm function) and eight had a score 
of four (a marker for no arm function). 
 
Majority of participants had already developed spasticity (as defined by Malhotra et al3) at the 
time of recruitment.  Almost all patients (38/40, i.e. 95%) demonstrated measurable forms of 
spasticity in the forearm flexors and 29/40 (72.5%) demonstrated velocity dependent spasticity.  
At the 6-months follow up measurement 26 of the 40 participants demonstrated some form of 
spasticity and 20 of these patients demonstrated velocity dependent spasticity. The primary 
reason for the missing values at the 6-month follow-up measurement was failure to obtain 
measurements when patients were not in the hospital setting. 
 
It was not feasible to use the Stroke Specific Quality of Life (SSQoL) measure. The SSQoL is a 
lengthy questionnaire-based assessment that relies heavily on the ability of the patient to 
understand verbal or written communication and select their chosen response to each question 
from a list of options.  The sample population in this study included patients who were not yet 
fully conscious or were drowsy in the early days following their stroke.  The sample also included 
patients with receptive, expressive and global aphasia.       
 
The patient resource collection was acceptable to patients. Completion rates fell overtime, but 
only slightly, and did not give the team cause for concern that this measure posed an 
unacceptable patient burden. The time point that caused most problems with completion was at 
baseline. It was felt this collection point could be sacrificed in favour of cost outcome 





The intervention cost was determined by taking the cost of the electrical stimulation machine 
discounted at 3.5% (as recommended in the Green Book by Her Majesty’s Treasury32) over 5 
years to yield an annual cost.  Twelve electrical stimulation machines were used in this study and 
it was assumed that for each patient using the machine they had a spare set of batteries and 
electrodes. The cost of the intervention also included the therapists’ time to receive training on 
how to deliver the intervention (4 x therapists at Band 6B for 1 hour), and Band 3 therapist 
support staff time to receive training on how to deliver the intervention (4 x support staff for 30 
minutes). The cost included the initial treatment time with the intervention by a Band 6 Therapist 
for 1 hour and further treatments delivered by support staff at Band 3 for 10 minutes per 
treatment (up to a total of 3).  The total costs of the electrical stimulation machines (discounted), 
replacement batteries, replacement electrodes, and the total costs of staff time was calculated 
and further divided by the number of electrical stimulation patients (20) to provide an estimate of 
the electrical stimulation intervention cost per patient. This was £37.90 per patient (see health 
economics supplementary file for details of how this figure was calculated). 
 
The study was focused on establishing the complete NHS and societal costs including those 
costs incurred by the patients and their families between the two groups, this included primary 
and secondary care costs associated with their arm function, out of pocket expenses and any 
effects on employment for either the patient or their carers’. This was completed at baseline, 3, 6 
and 12 month follow-ups.  
 
Table 3 displays the mean QALYs up to 12 months by the two arms. The results show that the 
intervention arm had higher QALY gains when compared to the usual care arm, however the 
incremental difference was small, and both groups improved over time.  
 
Table 4 displays the resource use costs of electrical stimulation and usual care up to 12 months. 
The usual care arm had higher costs compared to the electrical stimulation arm, from both the 
health service (NHS) and societal perspective. Electrical stimulation was therefore associated 
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with a lower consumption of resources and consequently lower costs, compared to those in the 
usual care arm. 
 
A bootstrap analysis was done based on the complete case analysis, a method to infer about 
likely population data from a sample set. (Electrical stimulation n=11; Usual Care n= 6).  
The scatter diagrams are presented in Figure 2 which represent the results from an NHS 
perspective and a societal perspective. The results show that the bootstrap replications cover all 
four quadrants of the cost effectiveness plane, indicating there is uncertainty around the 
interventions overall cost effectiveness, as would be expected in a feasibility pilot study. The 
majority of the points on the cost effectiveness plane were below the x-axis, indicating that 
electrical stimulation was less costly than the standard arm. The findings show that at 12 months, 





This study was able to demonstrate that it is feasible to recruit patients early after stroke (within 
72 hours) and for physiotherapists and occupational therapists to initiate electrical stimulation 
treatment of the wrist and finger extensor and flexor muscles.  Furthermore, once treatment was 
initiated it was possible to continue to deliver treatment in a way that was compliant with the 
protocol. It is possible that the training protocol and the educational booklets contributed to the 
enhanced compliance. However, there will be a need to adjust sample size by 32.5% if the 
identified primary end point is 12-month.  In this feasibility study, 17% of eligible patients were 
enrolled.  This high number of patients not included was not only due to the exclusion criteria but 
also due to the fact that the local specialist stroke service is an active research site with 
competing trials and many studies do not permit a patient to enrol in more than one active 
research trial. This was a barrier to recruitment at this site and is a factor that would need to be 




A common barrier for electrical stimulation of flexors is the fear that treatment with electrical 
stimulation could exacerbate spasticity. This study has demonstrated an important safety finding 
that treatment with electrical stimulation is unlikely to lead to spasticity or exacerbate spasticity. 
Furthermore, the electromyography (EMG), National Institute for Health Stroke Scale (NIHSS) 
arm score and Action Research Arm Test (ARAT) data demonstrated that it was possible for 
patients to have spasticity yet still regain arm function during the trial.   
 
An important aspect of this feasibility study was to determine the most suitable outcome 
measures for an ensuing definitive trial.  The aim of the electrical stimulation intervention was to 
prevent painful muscle contractures which can lead to a permanent joint deformity.  The primary 
outcome should therefore reflect this.  The objective measurement of passive range of 
movement, stiffness and spasticity as measured by Malhotra et al3 was not considered feasible 
for use in a large multi-centre trial due to complexity and cost of equipment, need for training, 
and the possibility of equipment failure.  A standard range of movement goniometer or 
measurement app for use on a tablet or mobile phone would be more feasible for use in any 
subsequent trial. 
 
The Scale of Pain Intensity (SPIN) was a feasible measure for use in this patient population to 
capture severity of pain in the affected arm.  The NIHSS, Barthel ADL Index, modified Rankin 
Scale, ARAT and Euro Qual 5D (five-level version) were feasible for measuring secondary 
outcomes in this patient population.  The Stroke Specific Quality of Life scale was not a suitable 
measure for this patient population.  The carer strain index was not suitable for completion at 
baseline and completion rates in general were low. In a future study it is recommended that carer 
burden is captured within the resource use questionnaire to reduce duplication and assessment 
burden.  The Montreal Cognitive Assessment (MoCA) was not feasible for use with all of the 
sample population as it requires the ability to communicate and also includes some pen and 
paper drawing tasks.  The sample population in this study included patients who were not yet 
fully conscious or were drowsy in the early days following their stroke.  Those participants who 
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had severe weakness in their usually dominant hand and arm were unable to complete the 
drawing and written tasks in the MoCA.  
 
The feasibility health economic evaluation demonstrated that the resource use questionnaire and 
EQ5D-5L could be used to capture economic data to determine cost effectiveness of the 
electrical stimulation intervention in a definitive trial and were acceptable to the patient group.  
They yield some promising early results in terms of an economic comparison of the treatment 
options.  It was felt the baseline data collection point for resource could possibly be sacrificed to 
reduce patient burden and an ICER calculated between the two arms of a trial. Early post-stroke 
is a traumatic time for patients and families and trying to establish patient and carer resource use 
at this time is problematic.  
 
In this feasibility study, limited resources meant that it was not possible to have an additional 
outcome assessor who was blinded to treatment allocation.  The outcome measures were 
objective and were unlikely to have been biased, however, future studies should use 
independent assessors if possible.  
 
Furthermore, there are limitations involved in interpreting the data due to the small sample size 
and therefore no definitive conclusions on efficacy can be drawn from this small sample. 
 
Arm weakness and post-stroke complications pose a considerable threat to the independence 
and productivity of stroke survivors. This feasibility study was important because it addressed the 
needs of a significant proportion of severely disabled stroke patients with a poor prognosis for 
recovery and at a high risk for secondary complications.  The ESCAPS feasibility study has data 
to inform the design of a multi-centre randomised controlled trial to evaluate the efficacy and 
cost-effectiveness of early electrical stimulation to the wrist flexors and extensors.  A suitably 
powered trial with blinded outcome assessors is warranted to determine effectiveness and cost 
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Assessed for eligibility 
(n=2,295) 
Excluded (n=2,255) 
   Not meeting inclusion criteria (n=2,080) 
   Declined to participate (n=22) 
   Other reasons (n=153) 
- Acutely unwell / end of life care (n=72) 
- Enrolled on other trials (n=40) 
- Lacked capacity and no consultee (n=25) 
- Lived out of area (n=10) 
- Already more than 72 hours post-stroke (n=6) 
-  
 
Baseline data analysis: Analysed (n=20) 
3m data analysis: Analysed (n=17) 
6m data analysis: Analysed (n=12) 




 Excluded from analysis (give reasons) (n=  ) 
3 month: Unable to follow-up (n=3) 
 Died (n=1) 
 Unable to contact (n=1) 
 Palliative care (n=1) 
6 month: Unable to follow-up (n=8) 
 Died (n=2) 
 Unable to contact (n=2) 
 Palliative care (n=4) 
12 month: Unable to follow-up (n=10) 
 Died (n=8) 
 Unable to contact (n=2) 
 
Allocated to usual care CONTROL (n=20) 
 Received allocated intervention (n=19) 
 Did not receive allocated intervention: 
- Died (n=1) 
 
3 month: Unable to follow-up (n=2) 
 Died (n=1) 
 Palliative care (n=1) 
6 month: Unable to follow-up (n=2) 
 Died (n=1) 
 Palliative care (n=1) 
12 month: Unable to follow-up (n=3) 
 Died (n=3) 
 
 
Allocated to ES INTERVENTION (n=20) 
 Received allocated intervention (n=19) 
 Did not receive allocated intervention: 
- Treatment protocol violation (n=1) 
  Baseline data analysis: Analysed (n=20) 
  3m data analysis: Analysed (n=18) 
  6m data analysis: Analysed (n=18) 










Table 1: Baseline characteristics of participants and baseline outcome measure data 






Age                 Median age 
                        IQR 
67 years 
59 – 84 years 
75 years 
66.5 – 80 years 
Gender           Male  n (%) 13 (65%) 7 (35%) 
Stroke classification 
Right sided                                         n (%) 
Ischaemic                                         n (%) 
NIHSS total score                         Median                                  










5 – 16.5 























1 – 3 days 
 
1.5 days 
0 – 3 days 




























































Pre-stroke NEADL Index 











NIHSS: National Institute for Health Stroke Scale; ARAT: Action Research Arm Test; mRS: modified 
Rankin Scale; SPIN: Scale of Pain Intensity; MoCA: Montreal Cognitive Assessment; NEADL: 











Table 2: 3, 6 & 12 month outcome measures and completion rates by treatment 
allocation 
 

























































































































































NIHSS: National Institute for Health Stroke Scale; ARAT: Action Research Arm Test; Barthel: Barthel 

































Table 3: QALYs* up to 12 months by treatment arms 
 
Complete Case 
  Electrical Stimulation Usual Care Difference 
QALYs 3 months 
(n=12) (n=10) 
Mean                           
(SD) 
Mean                           
(SD) 
Incremental       






(-0.066 to 0.073) 
QALYs 6 months 
(n=12) (n=6) 
 
Mean                           
(SD) 
Mean                           
(SD) 







(-0.143 to 0.191) 
QALYs 12 months 
(n=11) (n=6) 
 
Mean                           
(SD) 
Mean                           
(SD) 
Incremental       






(-0.183 to 0.424) 








































Table 4: The cost (£) derived from the resource use questionnaire by treatment group 





















































  Electrical 
Stimulation   
Usual Care   
Difference 
(n= 17) (n=10) 
  Mean                          
(SD) 
Mean                      
(SD) 




£650.51 £613.42 £37.09 
(£1,038.26) (£918.72) (-£781.12 to £855.31) 
Total private 
costs 
£1,427.99 £667.138 £760.86 
(£3,066.54) (£1,626.10) (-£1,419.65 to £2,941.37) 
Cost of lost 
productivity 
£0.00 £4,767.16 -£4,767.16 
(£0.00) (£11,051.05) (-£10,594.33 to £1,060.02) 
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Scatter graph plot above: Societal perspective 
 






















Supplementary File: Resource use table showing how the cost per patient was calculated. 
 
Resource Item Unit Cost 
(£) 
Source 
Cost of Intervention (ES)   
Cost of each ES machine £45.00 https://veritymedical.co.uk/ 
Discounted cost of ES machine 
at 3.5% over 5 years to yield an 
annual cost 
£9.97  
Total cost of (x12) ES 
machines 
£119.64  
Total cost of replacement 
batteries 
£40.00 https://veritymedical.co.uk/ 
Total cost of replacement 
electrodes 
£50.00 https://veritymedical.co.uk/ 
Total cost of therapists’ time to 
receive training on how to 
deliver the intervention (4 x 
therapists at Band 6 for 1 hour) 
£180.00 PSSRU2016 p.185, £45.00 per hour for Hospital Occupational 
Therapist (Band 6):  
Total cost of Band 3 therapist 
support staff time to receive 
training on how to deliver the 
intervention (4 x support staff 
for 30 minutes) 
£54.00 PSSRU2016 p.185, £27.00 per hour Band 3 therapist support 
staff  
Total cost of initial treatment 
time with the intervention by a 
Band 6 Therapist for 1 hour  
£45.00 PSSRU2016 p.185, £45.00 per hour for Hospital Occupational 
Therapist (Band 6): 
Total cost of further treatments 
delivered by support staff at 
Band 3 for 10 minutes per 
treatment (up to a total of 3). 
£270.00 PSSRU2016 p.185, £27.00 per hour Band 3 therapist support 
staff 
NHS Services     
Early Discharge Service  £125.20 Cost per visit to medical Rehabilitation Service (assumed 
outpatient rehab service): National schedule of reference costs 
year 2015 to 2016: 314 
Doctor (GP) Surgery £36.00 Average cost per contact with GP at surgery visit (average 
9.22min visit  (including carbon emissions (5 kgco2e)2(carbon 
costs less than £1) : PSSRU2016: p.144-145 
Doctor (GP) Home £92.04 Average cost per GP home visit (average 11.4 min visit plus 12 
min travel (PSSRU2015 p.177) time to visit at £236 per hour of 
patient contact): PSSRU2016: p.144-145 
Doctor (GP) Telephone £27.00 Cost per GP telephone contact (average 7.1min phone call at 
£27): PSSRU2015: p.177 
Practice Nurse at GP Surgery £14.47 Average cost per face to face contact with practice nurse at 
surgery (average surgery consultation at 15.5min at £56 per hr): 
PSSRU2015: p.174 
Community Nurse Home visit £33.50 Average cost per hour of patient-related work with community 
nurse at home (assumed 30min visit): PSSRU2015: p.169 
Occupational Therapist 
(Community) local clinic 
£22.00 Average cost per NHS community occupational therapist clinic 
visit (average 30 min visit: Curtis 2010): PSSRU2016: p.159 
Occupational Therapist 
(Community) at home 
£44.00 Average cost per NHS community occupational therapist home 
visit (average 60 min visit: Curtis 2010): PSSRU2016: p.159 
Physiotherapist (Community) 
local clinic 
£18.00 Average cost per community physiotherapist clinic visit (average 
30 min visit: Curtis 2010): PSSRU2014 p.179 
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Physiotherapist (Community) at 
home 
£36.00 Average cost per community physiotherapist home visit (average 
60 min visit: Curtis 2010): PSSRU2014 p.179 
Speech and Language 
Therapist (Community) local 
clinic 
£38.00 Cost per hour with hospital speech and language therapist 
(assumed hospital) PSSRU2015 p.219 
Speech and Language 
Therapist (Community) at 
home 
£38.00 Assumed same as cost per hour with hospital speech and 
language therapist (assumed hospital) PSSRU2015 p.219 
Community Social Services £79.00 Cost per session with social worker (£79 per hour of client-related 
work- assumed social worker for adult services): PSSRU2016 p. 
156 
      
Outpatient Appointments     
Cardiology department £127.67 Initial costs per visit to cardiology department as outpatient: 
National schedule of reference costs year 2015 to 2016:320 
Neurology department  £175.60 Initial costs per visit to Neurology department as outpatient: 
National schedule of reference costs year 2015 to 2016:400 
Physiotherapist (Hospital) £45.00 Initial costs per hour for Hospital Physiotherapist (assumed band 
6): PSSRU2016 p.185 
Occupational Therapist 
(Hospital) 
£45.00 Initial costs per hour to Hospital Occupational Therapist (assumed 
band 6): PSSRU2016 p.185 
A & E £146.86 Initial costs per visit to accident and emergency: National 
schedule of reference costs year 2015 to 2016:180 
Spasticity Clinic £175.60 Initial costs per visit to Spasticity Clinic - assumed same as visit to 
neurology department: National schedule of reference costs year 
2015 to 2016:400 
Splinting Services £175.60 Initial costs per visit to Splinting Services - assumed same as visit 
to neurology department: National schedule of reference costs 
year 2015 to 2016:400 
      
Prescribed Medication    BNF medicines complete 
     
 
 
Aids or Equipment 
    
Walking Frame £44.69 Mobiltysmart 
Crutches £23.59 Mobiltysmart 
Commode £61.77 PSSRU2013, p.109, average total cost *Prices inflated to 2016 
figures 
Raised Toilet Seat £32.51 PSSRU2013, p.109, average total cost *Prices inflated to 2016 
figures 
Wheelchair £138.36 Mobiltysmart 
Adaptive Cutlery £18.29 Mobiltysmart 
      
Stays     
Community Hospital £3,749.00 Average cost per day by point of delivery: assumed Elective 
inpatient (excluding excess bed days): National schedule of 
reference costs year 2015 to 2016:Table 2 p.10 
Residential Care Home £93.29 Cost per day for Private sector residential care for older people - 
£653 establishment cost plus personal living expenses per 
permanent resident week : PSSRU2016 p. 26 
Nursing Home - NHS £155.43 Cost per day for Local authority own-provision residential care for 
older people- £1,088 establishment cost plus personal living 
expenses per permanent resident week : PSSRU2016 p. 27 
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Nursing Home - Private £113.57 Cost per day for private sector nursing homes for older people -
£795 establishment cost plus personal living expenses per 
permanent resident week : PSSRU2016 p. 25 
Stay with Family / Friends £0.00 Assumed free 
      
Inpatient Stays (As a result 
of a stroke) 
    
  £10,573.00 Non-elective inpatient: Stroke with CC Score 16+ : Average 
Length of Stay - Days- 26:National schedule of reference costs 
year 2015 to 2016: AA35A 
  £7,422.00 Non-elective inpatient: Stroke with CC Score 13-15 : Average 
Length of Stay - Days- 18:National schedule of reference costs 
year 2015 to 2016: AA35B 
  £5,249.00 Non-elective inpatient: Stroke with CC Score 10-12 : Average 
Length of Stay - Days- 12:National schedule of reference costs 
year 2015 to 2016: AA35C 
  £3,927.00 Non-elective inpatient: Stroke with CC Score 7-9 : Average 
Length of Stay - Days- 9:National schedule of reference costs 
year 2015 to 2016: AA35D 
  £3,109.00 Non-elective inpatient: Stroke with CC Score 4-6 : Average 
Length of Stay - Days- 6:National schedule of reference costs 
year 2015 to 2016: AA35E 
  £2,385.00 Non-elective inpatient: Stroke with CC Score 0-3 : Average 
Length of Stay - Days- 5:National schedule of reference costs 
year 2015 to 2016: AA35F 
      
Cost of lost productivity     
Days off work (per day) £107.80 Median grossly day earning for full-time employees: ONS April 
2016 
 
 
